• Compass Therapeutics posted a Q2 net loss of USD 25.2 million, widening from USD 19.9 million a year earlier.
• Loss per share was USD 0.13, improving from USD 0.14 in the prior-year quarter.
• R&D expense rose 19% to USD 19.6 million, driven primarily by USD 2.6 million higher tovecimig-related spending.
• G&A expense climbed 59% to USD 7.4 million on USD 1.4 million higher pre-commercialization costs and USD 0.8 million higher stock compensation.
• Cash and marketable securities totaled USD 180 million at June 30, with management expecting funding into 2028 and FDA feedback in Q3 on tovecimig BTC data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005292), on August 06, 2026, and is solely responsible for the information contained therein.